H5N1 News and Research

Latest H5N1 News and Research

HHS awards Sanofi Pasteur 3-year, $56.94M egg supply contract for pandemic vaccine preparedness

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine at full capacity on a year-round basis.

11 Oct 2010

Study explains importance of identifying global pandemic risk factors to predict spread of diseases

A recent study led by Dr. Parviez Hosseini, a senior research fellow from EcoHealth Alliance (formerly Wildlife Trust), explains the importance of identifying global pandemic risk factors as early as possible, in order to predict the spread of diseases like H1N1 "swine" flu and SARS. "Predictive Power of Air Travel and Socio-Economic data for Early Pandemic Spread," recently published in the scientific publication PLoS ONE, examines the interplay among travel, trade, and national healthcare resources in predicting the emergence and spread of H1N1 and other viruses.

7 Oct 2010

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Medicago U.S.A. Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that company executives, along with U.S. Senator Kay Hagan (D-NC) and U.S. Congressman David Price (D-NC), are holding an official groundbreaking ceremony this morning for its U.S. plant-based commercial grade vaccine facility in Research Triangle Park, North Carolina.

1 Oct 2010

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®.

30 Sep 2010

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Inovio Pharmaceuticals and the University of Pennsylvania have received a grant of $3.1 million from the National Institutes of Health (NIH) Director's Office to further fund Inovio's universal SynCon™ flu vaccine development.

30 Sep 2010

AJMS journal provides research update on new infectious pathogens

Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.

24 Sep 2010

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had reached an agreement with Seaside 88, LP a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.

23 Sep 2010

MIDAS researchers continue to model how H1N1 may spread

As the United States prepares for the upcoming flu season, a group of researchers supported by the National Institutes of Health continues to model how H1N1 may spread.

22 Sep 2010

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it has reestablished efforts to advance the Aethlon Hemopurifier within U.S. Government programs that support the development and purchase of treatment countermeasures against bioterror threats.

21 Sep 2010

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

18 Sep 2010

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.

15 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its researchers have demonstrated the ability of the Aethlon Hemopurifier® to capture immunosuppressive exosomes derived from individuals with metastatic melanoma.

9 Sep 2010

Research provides new framework for quantifying risk of avian-borne diseases

In 2005 an outbreak of the H5N1 'bird flu' virus in South East Asia led to widespread fear with predictions that the intercontinental migration of wild birds could lead to global pandemic.

4 Sep 2010

Medicago included in President's report that examines drugs to prevent spread of infectious diseases

Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it was included in a report of President Obama's Council of Advisors on Science and Technology entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza", which was released earlier this month. U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials held a briefing to discuss this report and the $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases.

31 Aug 2010

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Nanotherapeutics, Inc., announced that it has filed an Investigational New Drug (IND) Application with the Food and Drug Administration (FDA) for NanoDTPA™ an orally administered capsule that is a less invasive treatment alternative to the FDA approved injectable Zn-DTPA (diethylenetriamine pentacetic acid). DTPA is used to remove radioactive compounds from the body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable fine particle formulation that allows DTPA to be absorbed into the body from the gastrointestinal tract.

30 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Scientists identify compound to treat Chagas' disease

A new compound may offer an effective drug candidate against the deadly tropical infection, Chagas' disease say researchers from Brazil. They report their findings in the August 2010 issue of the journal Antimicrobial Agents and Chemotherapy.

21 Aug 2010

Intercell reports significant increase in second quarter revenue

Today, Intercell AG announced its financial results for Q2 and H1 2010.IXIARO/JESPECT sales increased significantly from EUR 2.4m in Q2 2009 to EUR 5.2m in Q2 2010 Continued focus on growing marketing and sales of product in traveler and military markets

17 Aug 2010

H5N1 News and Research

Latest H5N1 News and Research

HHS awards Sanofi Pasteur 3-year, $56.94M egg supply contract for pandemic vaccine preparedness

Study explains importance of identifying global pandemic risk factors to predict spread of diseases

Medicago announces official groundbreaking ceremony for U.S. plant-based commercial grade vaccine facility

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

NIH awards $3.1 million to further fund Inovio's universal SynCon flu vaccine development

AJMS journal provides research update on new infectious pathogens

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

MIDAS researchers continue to model how H1N1 may spread

Aethlon Medical reestablishes efforts to advance Aethlon Hemopurifier

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Aethlon Hemopurifier captures immunosuppressive exosomes from individuals with metastatic melanoma.

Research provides new framework for quantifying risk of avian-borne diseases

Medicago included in President's report that examines drugs to prevent spread of infectious diseases

Nanotherapeutics files NanoDTPA IND for treatment of radiation exposure

Aethlon Medical receives approval for Chronic HCV Infection treatment

Scientists identify compound to treat Chagas' disease

Intercell reports significant increase in second quarter revenue

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

H5N1 News and Research

Latest H5N1 News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in